Please wait while the formulary information is being retrieved.
Drug overview for WYOST (denosumab-bbdz):
Generic name: DENOSUMAB-BBDZ (den-OH-sue-mab)
Drug class: Hypercalcemia Agents
Therapeutic class: Endocrine
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: DENOSUMAB-BBDZ (den-OH-sue-mab)
Drug class: Hypercalcemia Agents
Therapeutic class: Endocrine
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for WYOST (denosumab-bbdz) have been approved by the FDA:
Indications:
Giant cell tumor of bone
Humoral hypercalcemia of malignancy
Prevention of skeletal related events associated with bone metastases from solid tumor
Prevention of skeletal related events in multiple myeloma
Professional Synonyms:
Hypercalcemia associated with cancer
Hypercalcemia associated with malignancy
Hypercalcemia of malignancy
Malignant hypercalcemia
Indications:
Giant cell tumor of bone
Humoral hypercalcemia of malignancy
Prevention of skeletal related events associated with bone metastases from solid tumor
Prevention of skeletal related events in multiple myeloma
Professional Synonyms:
Hypercalcemia associated with cancer
Hypercalcemia associated with malignancy
Hypercalcemia of malignancy
Malignant hypercalcemia
The following dosing information is available for WYOST (denosumab-bbdz):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| WYOST 120 MG/1.7 ML VIAL | Maintenance | Adults inject 1.7 milliliters (120 mg) by subcutaneous route every 4 weeks |
No generic dosing information available.
The following drug interaction information is available for WYOST (denosumab-bbdz):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| IgG Antibodies and Derivatives/Efgartigimod-alfa SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3) CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3) DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3) |
VYVGART, VYVGART HYTRULO |
| IgG Antibodies and Derivatives/Nipocalimab-aahu SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3) CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3) DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3) |
IMAAVY |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| IgG Antibodies and Derivatives/Rozanolixizumab-noli SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3) CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3) DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3) |
RYSTIGGO |
The following contraindication information is available for WYOST (denosumab-bbdz):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 6 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Congenital long QT syndrome |
| Hypocalcemia |
| Pregnancy |
| Severe infection |
There are 6 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Diabetes mellitus |
| Hypoparathyroidism |
| Invasive dental procedure |
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
| Periodontitis |
| Thyroid surgery |
The following adverse reaction information is available for WYOST (denosumab-bbdz):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 29 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dyspnea |
Hypertension Hypokalemia Hypomagnesemia |
| Rare/Very Rare |
|---|
|
Anaphylaxis Angina Aseptic necrosis of jaw bone Atypical femoral fracture Cataracts Cellulitis Cholesteatoma of external ear Dental abscess DRESS syndrome Endocarditis Erysipelas Hypercalcemia Hyperparathyroidism Hypersensitivity angiitis Hypersensitivity drug reaction Hypocalcemia Hypotension Infection Malignancy Osteonecrosis of external auditory canal Pancreatitis Polymyalgia rheumatica Severe infection Throat constriction Vasculitis |
There are 51 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Back pain Fatigue General weakness Hypophosphatemia Musculoskeletal pain Nausea Thrombocytopenic disorder |
Allergic dermatitis Anemia Anorexia Arthralgia Bone pain Bronchitis Constipation Cough Cystitis Diarrhea Dizziness Dyspepsia Eczema Flatulence Gastroesophageal reflux disease Headache disorder Hypercholesterolemia Infection of ear Insomnia Pain in extremities Peripheral edema Pharyngitis Pneumonia Pruritus of skin Sciatica Skin inflammation Skin rash Spinal osteoarthritis Upper abdominal pain Upper respiratory infection Urinary tract infection Vertigo Vomiting |
| Rare/Very Rare |
|---|
|
Alopecia Ear itching Earache Erythema Facial edema Hearing loss Herpes zoster Impacted cerumen Lichenoid dermatitis drug eruption Tinnitus Urticaria |
The following precautions are available for WYOST (denosumab-bbdz):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for WYOST (denosumab-bbdz):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for WYOST (denosumab-bbdz)'s list of indications:
| Giant cell tumor of bone | |
| C40 | Malignant neoplasm of bone and articular cartilage of limbs |
| C40.0 | Malignant neoplasm of scapula and long bones of upper limb |
| C40.00 | Malignant neoplasm of scapula and long bones of unspecified upper limb |
| C40.01 | Malignant neoplasm of scapula and long bones of right upper limb |
| C40.02 | Malignant neoplasm of scapula and long bones of left upper limb |
| C40.1 | Malignant neoplasm of short bones of upper limb |
| C40.10 | Malignant neoplasm of short bones of unspecified upper limb |
| C40.11 | Malignant neoplasm of short bones of right upper limb |
| C40.12 | Malignant neoplasm of short bones of left upper limb |
| C40.2 | Malignant neoplasm of long bones of lower limb |
| C40.20 | Malignant neoplasm of long bones of unspecified lower limb |
| C40.21 | Malignant neoplasm of long bones of right lower limb |
| C40.22 | Malignant neoplasm of long bones of left lower limb |
| C40.3 | Malignant neoplasm of short bones of lower limb |
| C40.30 | Malignant neoplasm of short bones of unspecified lower limb |
| C40.31 | Malignant neoplasm of short bones of right lower limb |
| C40.32 | Malignant neoplasm of short bones of left lower limb |
| C40.8 | Malignant neoplasm of overlapping sites of bone and articular cartilage of limb |
| C40.80 | Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb |
| C40.81 | Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb |
| C40.82 | Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb |
| C40.9 | Malignant neoplasm of unspecified bones and articular cartilage of limb |
| C40.90 | Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb |
| C40.91 | Malignant neoplasm of unspecified bones and articular cartilage of right limb |
| C40.92 | Malignant neoplasm of unspecified bones and articular cartilage of left limb |
| C41 | Malignant neoplasm of bone and articular cartilage of other and unspecified sites |
| C41.0 | Malignant neoplasm of bones of skull and face |
| C41.1 | Malignant neoplasm of mandible |
| C41.2 | Malignant neoplasm of vertebral column |
| C41.3 | Malignant neoplasm of ribs, sternum and clavicle |
| C41.4 | Malignant neoplasm of pelvic bones, sacrum and coccyx |
| C41.9 | Malignant neoplasm of bone and articular cartilage, unspecified |
| D48.0 | Neoplasm of uncertain behavior of bone and articular cartilage |
| Humoral hypercalcemia of malignancy | |
| E83.52 | Hypercalcemia |
| Prevention of skeletal related event in multiple myeloma | |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| Prevention of skeletal related events in bone metastases | |
| C79.51 | Secondary malignant neoplasm of bone |
Formulary Reference Tool